New immune drug targets Hard-to-Treat cancers in early trial
NCT ID NCT07156136
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called IMC-P115C in people with advanced cancers that have a specific protein (PRAME) and a certain immune type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The study will check safety and whether the drug works alone or with standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMC-P115C (an immune therapy that targets cancer cells with a protein called PRAME)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced cancers that have the PRAME protein.
What could go wrong
This is a very early Phase 1 trial with only 140 participants, so it is not yet known if the drug is safe or effective. There may be side effects, and the treatment may not shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research South Australia (CRSA)
RECRUITINGAdelaide, 5000, Australia
-
Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)
RECRUITINGToulouse, 31059, France
-
Fondazione IRCCS - Istituto Nazionale dei Tumori
RECRUITINGMilan, 20133, Italy
-
Hospital Universitari Vall d Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario Ramon y Cajal
RECRUITINGMadrid, 28034, Spain
-
Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals
RECRUITINGBarcelona, 08908, Spain
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Istituto Europeo di Oncologia
RECRUITINGMilan, 20141, Italy
-
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"
RECRUITINGNaples, 80131, Italy
-
Linear Clinical Research ltd.
RECRUITINGNedlands, 06009, Australia
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, 2065, Australia
-
START Madrid - Hospital Universitario Fundación Jiménez Díaz
RECRUITINGMadrid, 28040, Spain
-
UNICANCER - Centre Leon-Berard (CLB)
RECRUITINGLyon, 69008, France